These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 25044219)

  • 21. Pharmacokinetics of telbivudine in subjects with various degrees of renal impairment.
    Zhou XJ; Swan S; Smith WB; Marbury TC; Dubuc-Patrick G; Chao GC; Brown NA
    Antimicrob Agents Chemother; 2007 Dec; 51(12):4231-5. PubMed ID: 17875994
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of administration of vancomycin or linezolid to critically ill patients with impaired renal function.
    Rodriguez Colomo O; Álvarez Lerma F; González Pérez MI; Sirvent JM; García Simón M;
    Eur J Clin Microbiol Infect Dis; 2011 May; 30(5):635-43. PubMed ID: 21225305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and tolerability of BAY41-6551 in subjects with chronic kidney disease.
    Stass H; Corkery K; Gribben D; Eldon MA
    J Aerosol Med Pulm Drug Deliv; 2011 Aug; 24(4):191-9. PubMed ID: 21599533
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple-dose pharmacokinetics of linezolid during continuous venovenous haemofiltration.
    Meyer B; Kornek GV; Nikfardjam M; Karth GD; Heinz G; Locker GJ; Jaeger W; Thalhammer F
    J Antimicrob Chemother; 2005 Jul; 56(1):172-9. PubMed ID: 15905303
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.
    Treitel M; Marbury T; Preston RA; Triantafyllou I; Feely W; O'Mara E; Kasserra C; Gupta S; Hughes EA
    Clin Pharmacokinet; 2012 Sep; 51(9):619-28. PubMed ID: 22799589
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The pharmacokinetics of linezolid are not affected by concomitant intake of the antioxidant vitamins C and E.
    Gordi T; Tan LH; Hong C; Hopkins NJ; Francom SF; Slatter JG; Antal EJ
    J Clin Pharmacol; 2003 Oct; 43(10):1161-7. PubMed ID: 14517199
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linezolid in the central nervous system: comparison between cerebrospinal fluid and plasma pharmacokinetics.
    Viaggi B; Paolo AD; Danesi R; Polillo M; Ciofi L; Del Tacca M; Malacarne P
    Scand J Infect Dis; 2011 Sep; 43(9):721-7. PubMed ID: 21585240
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ocular penetration of linezolid after oral administration in rabbits.
    Saleh M; Lefevre S; Bourcier T; Prevost G; Gaucher D; Speeg-Schatz C; Jehl F
    J Ocul Pharmacol Ther; 2011 Jun; 27(3):243-6. PubMed ID: 21510740
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections.
    MacGowan AP
    J Antimicrob Chemother; 2003 May; 51 Suppl 2():ii17-25. PubMed ID: 12730139
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Population Pharmacokinetics of Colistin Methanesulfonate and Colistin in Critically Ill Patients with Acute Renal Failure Requiring Intermittent Hemodialysis.
    Jacobs M; Grégoire N; Mégarbane B; Gobin P; Balayn D; Marchand S; Mimoz O; Couet W
    Antimicrob Agents Chemother; 2016 Jan; 60(3):1788-93. PubMed ID: 26729492
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and Safety of Omadacycline in Subjects with Impaired Renal Function.
    Berg JK; Tzanis E; Garrity-Ryan L; Bai S; Chitra S; Manley A; Villano S
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29158281
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The effects of intravenous iron treatment on oxidant stress and erythrocyte deformability in hemodialysis patients.
    Cavdar C; Temiz A; Yeniçerioğlu Y; Calişkan S; Celik A; Sifil A; Onvural B; Camsari T
    Scand J Urol Nephrol; 2003; 37(1):77-82. PubMed ID: 12745750
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
    Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
    J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacokinetics, safety, and tolerability of edoxaban in end-stage renal disease subjects undergoing haemodialysis.
    Parasrampuria DA; Marbury T; Matsushima N; Chen S; Wickremasingha PK; He L; Dishy V; Brown KS
    Thromb Haemost; 2015 Apr; 113(4):719-27. PubMed ID: 25566930
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin resistance in dialysis versus non dialysis end stage renal disease patients without diabetes.
    Satirapoj B; Supasyndh O; Phantana-Angkul P; Ruangkanchanasetr P; Nata N; Chaiprasert A; Kanjanakul I; Choovichian P
    J Med Assoc Thai; 2011 Sep; 94 Suppl 4():S87-93. PubMed ID: 22043573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics of anakinra in subjects with different levels of renal function.
    Yang BB; Baughman S; Sullivan JT
    Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic studies of linezolid and teicoplanin in the critically ill.
    Whitehouse T; Cepeda JA; Shulman R; Aarons L; Nalda-Molina R; Tobin C; MacGowan A; Shaw S; Kibbler C; Singer M; Wilson AP
    J Antimicrob Chemother; 2005 Mar; 55(3):333-40. PubMed ID: 15705641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Alveolar diffusion and pharmacokinetics of linezolid administered in continuous infusion to critically ill patients with ventilator-associated pneumonia.
    Boselli E; Breilh D; Caillault-Sergent A; Djabarouti S; Guillaume C; Xuereb F; Bouvet L; Rimmelé T; Saux MC; Allaouchiche B
    J Antimicrob Chemother; 2012 May; 67(5):1207-10. PubMed ID: 22351682
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of intravitreal administrations of linezolid in an experimental model of S. aureus-related endophthalmitis.
    Saleh M; Lefèvre S; Acar N; Bourcier T; Marcellin L; Prévost G; Subilia A; Gaucher D; Jehl F
    Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4832-41. PubMed ID: 22661478
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease.
    Courtney R; Sansone A; Smith W; Marbury T; Statkevich P; Martinho M; Laughlin M; Swan S
    J Clin Pharmacol; 2005 Feb; 45(2):185-92. PubMed ID: 15647411
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.